SUFU
SUFU (Suppressor of fused homolog) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Lung cancer, Medulloblastoma and 3 more.
Overview
Negative regulator in the hedgehog/smoothened signalling pathway that acts by sequestering the GLI (GI1, GLI2 and GLI3) transcription factors in the cytoplasm. When smoothened signalling is initiated, GLI transcription factors dissociate from SUFU, translocate to the nucleus and activate expression of target genes. In absence of smoothened signalling, the SUFU-GLI3 complex is recruited to cilia, leading to the efficient processing of full-length GLI3 into transcription repressor GLI3R: SUFU participates to GLI3 processing by promoting recruitment of GSK3B to GLI3.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Sonidegib. Open Targets scores its association with cancer at 0.71 (direct and indirect evidence; datatypes literature 0.92, animal model 0.54, genetic association 0.34, somatic mutation 0.88). IntOGen calls it a driver in 1 cohort (0 activating, 1 loss-of-function), covering Pilocytic Astrocytoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · SUFU (Suppressor of fused homolog) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Lung cancer, Medulloblastoma and 3 more.
- 1 · What it is
SUFU (Suppressor of fused homolog) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Lung cancer, Medulloblastoma and 3 more.
- 2 · What goes wrong in cancer
Negative regulator in the hedgehog/smoothened signalling pathway that acts by sequestering the GLI (GI1, GLI2 and GLI3) transcription factors in the cytoplasm.
- 3 · How drugs use it
No product in this corpus aims at SUFU yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:16466 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9UMX1 (protein name, function text, keywords and locations (REST API)); CIViC gene SUFU (1 evidence items, 0 assertions, 1 variants; diseases: Medulloblastoma (GraphQL API, CC0)); Open Targets ENSG00000107882 (association with cancer (MONDO_0004992) 0.71; per-cancer scores at or above 0.5: melanoma 0.54, skin cancer 0.57, medulloblastoma 0.80, lung cancer 0.51, meningioma 0.72 (GraphQL API, CC0)); IntOGen SUFU (driver in 1 cohort (Act 0, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Negative regulator in the hedgehog/smoothened signalling pathway that acts by sequestering the GLI (GI1, GLI2 and GLI3) transcription factors in the cytoplasm. When smoothened signalling is initiated, GLI transcription factors dissociate from SUFU, translocate to the nucleus and activate expression of target genes. In absence of smoothened signalling, the SUFU-GLI3 complex is recruited to cilia, leading to the efficient processing of full-length GLI3 into transcription repressor GLI3R: SUFU participates to GLI3 processing by promoting recruitment of GSK3B to GLI3. May also act as a negative regulator of beta-catenin signalling. Required for normal embryonic development. Required for the proper formation of hair follicles and the control of epidermal differentiation. Location: Cytoplasm; Nucleus; Cell projection, cilium (UniProt). Locus 10q24.32 (HGNC).
- Skin cancer: Open Targets association 0.57 with skin cancer (MONDO_0002898)
- Lung cancer: Open Targets association 0.51 with lung cancer (MONDO_0008903)
- Medulloblastoma: Open Targets association 0.80 with medulloblastoma (MONDO_0007959); CIViC evidence names this disease
- Meningioma: Open Targets association 0.72 with meningioma (MONDO_0016642)
- Paediatric low-grade glioma: IntOGen driver in 1 cohort (PAST)
- Melanoma: Open Targets association 0.54 with melanoma (MONDO_0005105)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"SUFU" OR ABSTRACT:"SUFU" OR TITLE:"SUFU negative regulator of hedgehog signaling" OR ABSTRACT:"SUFU negative regulator of hedgehog signaling" OR TITLE:"Suppressor of fused homolog" OR ABSTRACT:"Suppressor of fused homolog" OR TITLE:"SUFUH" OR ABSTRACT:"SUFUH" OR TITLE:"SUFUXL" OR ABSTRACT:"SUFUXL" OR TITLE:"PRO1280" OR ABSTRACT:"PRO1280") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SUFU, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetCBLB
Shares Lung cancer (all types), Skin cancer (all types), CIViC, IntOGen.
- TargetCRLF2
Shares Lung cancer (all types), Skin cancer (all types), CIViC, IntOGen.
- TargetWAS
Shares Medulloblastoma, Skin cancer (all types), IntOGen, Melanoma.
- TargetCDX2
Shares Lung cancer (all types), Skin cancer (all types), CIViC, IntOGen.
- TargetCIITA
Shares Lung cancer (all types), Skin cancer (all types), CIViC, IntOGen.
- TargetGNA11
Shares Lung cancer (all types), Skin cancer (all types), CIViC, IntOGen.
- TargetSMAD3
Shares Lung cancer (all types), Skin cancer (all types), CIViC, IntOGen.
- TargetDDX3X
Shares Medulloblastoma, Lung cancer (all types), Skin cancer (all types), CIViC.